European Commission logo
English English
CORDIS - EU research results
Content archived on 2024-05-24

Hypotensive peptides from milk proteins


Milk protein peptides can inhibit angiotensin-I-converting enzyme (ACE) Drugs, which inhibit ACE, are in widespread use in cardiovascular medicine. Little or no information is available on the physiological efficacy in man of ingesting natural milk protein peptides/hydrolysis's, which inhibit ACE in vitro. Therefore, it is proposed to address this European-wide functional food ingredient problem/opportunity. The proposal objectives are to perform a detailed physiological, physicochemical, immunochemical and catechetical characterisation, in addition to a consumer assessment of these naturally derived inhibitors of ACE. Milk proteins will be hydrolysed using food-grade proteases. Clinical/bio availability trials will be performed in human volunteers. Immunochemical studies will use serum samples from humans fed ACE inhibitory hydrolysis. Catechetical studies will use human cell culture systems. Consumer awareness will be assessed on a global basis. The outcome of this proposal should lead to the development of clinically validated health claims in respect to the physiological efficiency and safety of ingesting milk protein-derived inhibitors of ACE.

Call for proposal

Data not available


EU contribution
No data
Plassey Technological Park

See on map

Total cost
No data

Participants (3)